Intramuscular

Intramuscular injection (abbreviated IM) delivers a substance directly into muscle tissue rather than into a vein or beneath the skin. From there it diffuses into surrounding capillaries and enters systemic circulation — a path that bypasses the gastrointestinal tract and avoids first-pass metabolism in the liver.

The most common injection sites are the deltoid of the upper arm, the vastus lateralis of the outer thigh, and the gluteus. In clinical settings the term is simply intramuscular; in emergency and lay contexts it is sometimes called a muscle shot. The abbreviation IM is standard across both.

Onset & absorption

IM absorption is faster than oral dosing because the substance reaches circulation without passing through the gut or liver, so a greater proportion arrives intact compared with swallowing. The rise in effect is more gradual than intravenous delivery, which places a substance directly into the bloodstream, but faster and more consistent than subcutaneous injection in most circumstances.

Because the substance must diffuse out of muscle tissue before reaching capillaries, there is a meaningful interval between injection and peak effect. This makes moment-to-moment titration harder than with IV delivery, though the slower rise also provides a modest buffer compared to the near-immediate onset of an intravenous dose.

Harm reduction

The risks of IM injection include those common to all needle-based routes — infection at the injection site, abscess formation, and bloodborne pathogen transmission through shared equipment — as well as risks specific to muscle tissue.

Injecting too close to a nerve can cause pain, weakness, or lasting damage; the sciatic nerve is a significant concern with gluteal injections. Accidentally entering a blood vessel converts an IM dose to an unintended IV dose, compressing the onset curve sharply and reducing the margin for error.

Repeated injection at the same site causes local fibrosis: scar tissue accumulates in the muscle, impairing future absorption and potentially restricting movement. Oil-based preparations can cause granuloma formation if injected incorrectly or at unsuitable sites.

What varies by substance

The IM route establishes a broad absorption pattern, but the specifics differ considerably from substance to substance. Some compounds are formulated specifically for IM use — including long-acting depot preparations designed to release gradually over days or weeks rather than minutes — while others are not suitable for muscle injection at all, causing tissue necrosis or severe local pain.

The physical chemistry of the preparation matters as well: water-soluble formulations typically absorb more rapidly than oil-based ones, and the osmolality and pH of the solution affect both local tolerability and the rate of diffusion into capillaries. What the intramuscular route provides is systemic access without venous cannulation; the pharmacokinetics, formulation requirements, and contraindications that follow belong to each substance's own record.